Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note released on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Up 5.1 %

NASDAQ CPIX opened at $1.65 on Tuesday. The stock has a market cap of $23.40 million, a PE ratio of -3.75 and a beta of 0.16. Cumberland Pharmaceuticals has a fifty-two week low of $1.43 and a fifty-two week high of $2.36. The business has a 50 day moving average price of $1.89 and a two-hundred day moving average price of $1.88. The company has a quick ratio of 1.11, a current ratio of 1.28 and a debt-to-equity ratio of 0.44.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. The business had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CPIX. Millennium Management LLC purchased a new position in shares of Cumberland Pharmaceuticals during the 4th quarter valued at approximately $46,000. Bank of New York Mellon Corp purchased a new position in shares of Cumberland Pharmaceuticals during the 3rd quarter valued at approximately $142,000. Acadian Asset Management LLC boosted its stake in shares of Cumberland Pharmaceuticals by 27.8% during the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock valued at $529,000 after buying an additional 40,949 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Cumberland Pharmaceuticals by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after buying an additional 38,100 shares during the last quarter. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.